

# Sustained Improvements in Psoriasis Area and Severity Index and in Percent Body Surface Area of Psoriasis With JNJ-77242113 in Patients With Moderate-to-Severe Plaque Psoriasis: Treat-to-Target Analyses in the FRONTIER 1 & 2 Studies



Kim A. Papp,<sup>1</sup> Laura K. Ferris,<sup>2</sup> Andreas Pinter,<sup>3</sup> Phoebe Rich,<sup>4</sup> Ronald Bernard Vender,<sup>5</sup> Andrew E. Pink,<sup>6</sup> Takayuki Ota,<sup>7</sup> Yaung-Kaung Shen,<sup>8</sup> Shu Li,<sup>8</sup> Amy M. DeLozier,<sup>8</sup> Jessica Vasquez,<sup>9</sup> Ya-Wen Yang,<sup>9</sup> Robert Bissonnette<sup>10</sup>

<sup>1</sup>Alliance Clinical Trials and Probiy Medical Research, Waterloo, ON, Canada; <sup>2</sup>Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada; <sup>3</sup>University of Pittsburgh, Pittsburgh, PA, USA; <sup>4</sup>Goethe University Frankfurt, Frankfurt, Germany; <sup>5</sup>Oregon Dermatology and Research Center, Portland, OR, USA; <sup>6</sup>McMaster University, Hamilton, ON, Canada; <sup>7</sup>St. John's Institute of Dermatology, Guy's & St. Thomas' NHS Foundation Trust, London, England, UK; <sup>8</sup>Johnson & Johnson, San Diego, CA, USA; <sup>9</sup>Johnson & Johnson, Spring House, PA, USA; <sup>10</sup>Johnson & Johnson, Horsham, PA, USA; <sup>11</sup>Innovaderm Research, Montreal, QC, Canada

## Background


- Defined thresholds for Psoriasis Area and Severity Index (PASI) and psoriatic body surface area (BSA) are relevant disease endpoints that inform treat-to-target (T2T) management strategies in psoriasis (PsO)<sup>1,2</sup>
- Interleukin (IL)-23 pathway inhibition via monoclonal antibodies has demonstrated efficacy and safety in patients with moderate-to-severe PsO<sup>3</sup>
- Currently, no oral therapies selectively target the IL-23 pathway

- JNJ-77242113 (JNJ-2113)**
- First and only targeted oral peptide that inhibits IL-23 signaling by binding to the IL-23 receptor
  - Showed superior clinical efficacy vs placebo (PBO) in the phase 2 FRONTIER 1 study, which was durable through 1 year of the FRONTIER 2 long-term extension (LTE) study, in patients with moderate-to-severe plaque PsO<sup>4,5</sup>

## Objectives

- To assess the effect of JNJ-2113 on the achievement of defined treatment goals in patients with moderate-to-severe plaque PsO through 1 year in FRONTIER 1 and 2

## Methods




## Results

**FRONTIER 1 participants had established, moderate-to-severe plaque PsO**


	PBO (N=43)	25 mg QD (N=43)	25 mg BID (N=41)	50 mg QD (N=43)	100 mg QD (N=43)	100 mg BID (N=42)	All (N=212)	All Groups (N=255)
<b>Demographics</b>								
Age, years	43.9 (14.7)	44.5 (12.7)	45.7 (11.9)	45.1 (11.1)	44.7 (14.1)	42.0 (11.3)	44.4 (12.2)	44.3 (12.6)
Female	42%	26%	29%	37%	26%	29%	29%	31%
White/Asian	86%/12%	70%/28%	66%/21%	72%/21%	81%/17%	71%/21%	72%/21%	74%/19%
Weight, kg	92.1 (24.7)	89.0 (19.4)	90.8 (22.1)	87.6 (19.2)	85.4 (22.5)	88.5 (16.9)	88.2 (20.0)	88.9 (20.9)
<b>Disease Characteristics</b>								
PsO disease duration, years	17.9 (14.4)	15.5 (11.8)	18.1 (11.8)	21.5 (11.2)	19.5 (13.3)	16.7 (13.8)	18.3 (12.5)	18.2 (12.8)
PASI (0-72)	19.0 (5.3)	18.9 (5.3)	18.5 (5.8)	19.2 (5.1)	18.4 (6.9)	20.3 (6.5)	19.1 (5.9)	19.0 (5.8)
Psoriatic BSA, %	26.1 (15.7)	21.1 (9.3)	20.9 (11.9)	23.9 (13.6)	20.5 (13.7)	24.2 (12.6)	22.1 (12.3)	22.8 (13.0)
IGA								
Moderate (3)/Severe (4)	88%/12%	70%/30%	80%/20%	84%/16%	81%/19%	71%/29%	77%/23%	79%/21%
<b>Medication use at baseline</b>								
Phototherapy <sup>a</sup>	44%	40%	37%	56%	49%	33%	43%	43%
Biologics <sup>b</sup>	16%	16%	32%	26%	21%	21%	23%	22%
Systemics <sup>c</sup>	79%	77%	80%	81%	79%	74%	78%	78%

Data shown are mean (SD) or percentage, unless otherwise indicated. <sup>a</sup>Includes PUVA or UVB. <sup>b</sup>Includes etanercept, infliximab, adalimumab, ustekinumab, brodalumab, secukinumab, ixekicimab, brodalumab, guselkumab, risankizumab, bimekizumab, tiludronamide, abatacept, efalizumab, natalizumab, certolizumab pegol. <sup>c</sup>Includes conventional nonbiologic systemic therapies, novel nonbiologic systemic therapies, L2S-vitamin D3 and analogs, phototherapy, and biologics. BID=Twice daily; BSA=Body surface area; IGA=Investigator's Global Assessment; JNJ-2113=JNJ-77242113; PASI=Psoriasis Area and Severity Index; PBO=Placebo; PsO=Psoriasis; PUVA=Psoralen plus ultraviolet A; QD=Once daily; SD=Standard deviation; UVB=Ultraviolet B.


**Percent improvements in PASI score were greater with JNJ-2113 than PBO as early as W4, with continued and sustained improvement over time**




**Greater proportions of JNJ-2113-treated vs PBO-treated patients achieved absolute PASI thresholds of ≤5, ≤3, and ≤2 at W16; rates were maintained at W52**




**Greater proportions of JNJ-2113-treated vs PBO-treated patients achieved stringent PASI thresholds of ≤1 and 0 at W16; rates were maintained or increased at W52**



**Greater proportions of JNJ-2113-treated vs PBO-treated patients achieved PsO BSA thresholds of ≤3% and ≤1% at W12 and/or W16; rates were maintained or increased at W52**



**86% and 82% of patients treated with 100 mg BID achieving BSA ≤3% and ≤1% at W16, respectively, maintained response at W52**



**PRESENTED AT:** Masterclasses in Dermatology, Sarasota, FL, USA; February 20-23, 2025. **REFERENCES:** 1. Muhl, SK. *J Dermatol*. 2020;38(2):1158-66. 2. Armstrong, AW. *J Am Acad Dermatol*. 2017;76:290-8. 3. Vu, A. *Expert Opin Biol Ther*. 2022;22:1489-502. 4. Bissonnette, R. *N Engl J Med*. 2024;390:510-21. 5. Ferris, LK. Oral presentation 66768. AAD Annual Meeting, March 8-12, 2024; San Diego, CA, USA. 6. Fredriksson, T. *Dermatologica*. 1978;157:238-44. **ACKNOWLEDGMENTS:** Layout design and reformatting for this e-poster presentation was provided by Mugdha Rokade of SRO Medical Writing Pvt Ltd, Thane, India. Medical writing support was provided by JSS Medical Research, Inc., under the direction of the authors in accordance with Good Publication Practice guidelines (Ann Intern Med. 2022;175:1288-304). Sponsored by Johnson & Johnson. **DISCLOSURES:** KAP: Clinical research grants, honoraria, and/or consultant; scientific advisor, investigator, speaker, and/or medical officer; AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celtrion, Concert Pharmaceuticals, Dermavant, Dermira, Dice Pharmaceuticals, Dice Therapeutics, Eli Lilly, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sayofi/Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, Inc., UCSF, Zai Lab Co., Ltd. LKF: Investigator; AbbVie, Acelyrin, Amgen, Apogee, Arcutis, Arista, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, DermTech, Eli Lilly, Galderma, GRAL, Incyte, Janssen, LEO Pharma, Moberg, Mobius, Novartis, Regeneron, SkinAnalytics, Takeda, UCSF, Consultant; AbbVie, Amgen, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, DermTech, Janssen, LEO Pharma, MCZ, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough, Tigeract Pharma, UCS Pharma, and Zuelwig Pharma. PB: Principal investigator; AbbVie, Acelyrin, Amgen, Arcutis, AstraZeneca, Bristol Myers Squibb, Celtrion, Celgene, Cytoskeleton, Dermavant, Eli Lilly, Galderma, GSK, Immunomed, Janssen, Kabi-Care, LEO Pharma, Meiji Seika, Novartis, Pfizer, Regeneron, Sandoz, Sun, Takeda, UCS, Vectria/Mylan, AEP; Investigator, advisor and/or speaker and/or received educational support from AbbVie, Almiral, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, UCS, TO, Y-KS, SL, AM, JD, JV, and Y-WY; Employees of Johnson & Johnson; employees may own stock/stock options in Johnson & Johnson. RB: Advisory board member, consultant, speaker and/or investigator and received honoraria and/or grants; AbbVie, Alumis, Amgen, Arcutis, Bausch Health, Boston, Bristol Myers Squibb/Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, Nimbus, Novartis, Pfizer, Regeneron, UCS, VectriaBio and Xenor; also an employee and shareholder of Innovaderm Research. **PREVIOUSLY PRESENTED AT:** EADV Congress 2024; Amsterdam, The Netherlands; September 25-28, 2024.